Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
Activation of the estrogen receptor (ER) by hormone involves at least two steps. First, hormone binding initially relieves repression, a property imposed on ER in cis by its ligand-binding domain (EBD). Subsequently, the derepressed ER binds specific genomic sites and regulates transcription. In addition to the natural hormone, ER binds a broad range of ligands that evoke a spectrum of responses ranging from full ER activation by agonists to partial activation and inhibition by partial or complete antagonists. How these different ligands evoke different ER responses remains unclear. To address this issue, we have developed a nontranscriptional assay for ER ligand responsiveness based on Flp recombinase/human EBD protein chimeras. These fusion proteins transduce the transient event of ligand binding into a permanent DNA change in a human cell line system. A fusion protein including ER D, E, and F domains was activated by all the ER ligands tested, demonstrating that both agonists and antagonists serve to relieve initial repression, and that differences between them lie downstream in the activation pathway. Mutant variants of the Flp-ER protein that distinguish between agonists and antagonists, and a mutant EBD that selectively lost the ability to respond to 17beta,-estradiol but not to other ligands, were also identified. Thus, agonists and antagonists can be functionally distinguished in a nontranscriptional assay.
Logie
C
C
Gene Expression Program, European Molecular Biology Laboratory, Heidelberg, Germany.
Nichols
M
M
Myles
K
K
Funder
J W
JW
Stewart
A F
AF
D004254:DNA Nucleotidyltransferases / Q000235:genetics* / Q000378:metabolism; D004054:Diethylstilbestrol / Q000494:pharmacology; D019281:Dimerization; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology*; D000077267:Fulvestrant; D006589:Hexestrol / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D010880:Piperidines / Q000494:pharmacology; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000819:agonists / Q000235:genetics* / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000494:pharmacology
D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; D011993:Recombinant Fusion Proteins; D013629:Tamoxifen; D006589:Hexestrol; C016601:afimoxifene; D000077267:Fulvestrant; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D004054:Diethylstilbestrol; D004254:DNA Nucleotidyltransferases; C045119:FLP recombinase